03 Feb 2025
// FDA
11 Mar 2024
// DRUG STORE NEWS
26 Feb 2024
// PR NEWSWIRE
Aucta is a global brand that creates better products from proven molecules.
About
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Attending
28-30 October, 2025
Industry Trade Show
Attending
05-09 December, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Attending
28-30 October, 2025
Industry Trade Show
Attending
05-09 December, 2025
CORPORATE CONTENT #SupplierSpotlight
03 Feb 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218380
11 Mar 2024
// DRUG STORE NEWS
26 Feb 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aucta-pharmaceuticals-inc-aucta-pharmaceuticals-launches-motpoly-xr-lacosamide-extended-release-capsules-c-v-the-first-and-only-once-daily-formulation-of-lacosamide-302070783.html
05 Dec 2022
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aucta-announced-fda-approval-of-a-generic-version-of-trileptaloxcarbazepine-oral-suspension-301694327.html#:~:text=PISCATAWAY%2C%20N.J.%2C%20Dec.,this%20product%20in%20early%202023.
01 Dec 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/aucta-announces-fda-approval-of-a-generic-version-of-perforomist-formoterol-fumarate-inhalation-solution-301691187.html
30 Nov 2022
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215332
RLD : No
TE Code : AN
Dosage Form : SOLUTION; INHALATION
Proprietary Name : ARFORMOTEROL TARTRATE
Dosage Strength : EQ 0.015MG BASE/2ML
Approval Date : 2025-02-03
Application Number : 218380
RX/OTC/DISCN : RX
RLD : No
TE Code : AN
RLD : No
TE Code : AB
Dosage Form : GRANULE; ORAL
Proprietary Name : DEFERASIROX
Dosage Strength : 90MG
Approval Date : 2021-03-09
Application Number : 214559
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Dosage Form : GRANULE; ORAL
Proprietary Name : DEFERASIROX
Dosage Strength : 180MG
Approval Date : 2021-03-09
Application Number : 214559
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Dosage Form : GRANULE; ORAL
Proprietary Name : DEFERASIROX
Dosage Strength : 360MG
Approval Date : 2021-03-09
Application Number : 214559
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code :
Dosage Form : CAPSULE, EXTENDED RELEASE; ORA...
Proprietary Name : MOTPOLY XR
Dosage Strength : 100MG
Approval Date : 2023-05-04
Application Number : 216185
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Dosage Form : CAPSULE, EXTENDED RELEASE; ORA...
Proprietary Name : MOTPOLY XR
Dosage Strength : 150MG
Approval Date : 2023-05-04
Application Number : 216185
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Dosage Form : CAPSULE, EXTENDED RELEASE; ORA...
Proprietary Name : MOTPOLY XR
Dosage Strength : 200MG
Approval Date : 2023-05-04
Application Number : 216185
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code : AB
Dosage Form : SUSPENSION; ORAL
Proprietary Name : OXCARBAZEPINE
Dosage Strength : 300MG/5ML
Approval Date : 2022-11-30
Application Number : 215332
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AA
Dosage Form : FOR SOLUTION; ORAL
Proprietary Name : VIGADRONE
Dosage Strength : 500MG/PACKET
Approval Date : 2018-06-21
Application Number : 210196
RX/OTC/DISCN : RX
RLD : No
TE Code : AA
ABOUT THIS PAGE